VEGFA and neoplasm: EWS xenograft models have also showed delayed tumor progression with anti-VEGF directed therapies; however, rebound tumor growth occurred after therapy was discontinued, suggesting single agent VEGF-directed therapy may have limited success in the treatment of pediatric sarcomas (229, 230).